Skip to main content
Clinical Trials/ACTRN12612000703808
ACTRN12612000703808
Completed
未知

A cross-sectional cohort to assess the age-related changes to the function and morphology of the meibomian glands and the association of these changes to symptomatology in healthy people aged between 25 and less than 65 years of age

Brien Holden Vision Institute0 sites200 target enrollmentJuly 2, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Meibomian gland dysfunction
Sponsor
Brien Holden Vision Institute
Enrollment
200
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 2, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Brien Holden Vision Institute

Eligibility Criteria

Inclusion Criteria

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent
  • Be aged between 25 and less than 65 years old, male or female
  • Have ocular health findings considered to be normal”

Exclusion Criteria

  • Any pre\-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids (excluding dry eye).
  • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, androgen deficiency and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome, acne rosacea and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
  • Concurrent punctal occlusion
  • Use of or a need for concurrent category S4 and above ocular medication at enrolment and/or during the clinical trial.
  • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology either in an adverse or beneficial manner at enrolment and/or during the clinical trial e.g. hormone replacement therapy or anti\-androgen therapy.
  • NB: Systemic antihistamines are allowed on an as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
  • Eye surgery within 12 weeks immediately prior to enrolment for this trial.
  • Previous corneal refractive surgery.
  • Known allergy or intolerance to ingredients in any of the diagnostic products used during the clinical trial.
  • Currently enrolled in another clinical trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials